Oncology Institute, INC Form 4 insider transactions

Jorey Chernett, a Director and 10% owner of Oncology Institute, Inc., acquired 50,000 shares of common stock at a weighted average price of $3.15 per share.

Jorey Chernett, a Director and 10% owner of The Oncology Institute, Inc., acquired 125,000 shares of common stock at an average price of $3.11 per share.

Oncology Institute Director and 10% owner Jorey Chernett acquired 25,000 shares of common stock for $3.35 per share in a pre-planned transaction.

Jorey Chernett, a Director and 10% owner of Oncology Institute, Inc., significantly increased his beneficial ownership through multiple common stock purchases.

The Oncology Institute's CFO, Robert Ross Carter, filed an amended Form 4 to correct details of a stock sale made to cover tax liabilities from an RSU award.

The Oncology Institute's CFO, Robert Ross Carter, sold 247 shares of common stock to cover tax liabilities from an RSU award vesting.

The Oncology Institute Director Brad Hively sold 13,333 shares of common stock on December 15, 2025, to cover tax liabilities from a recent RSU award vesting.

Gabriel Ling, a Director and 10% owner of The Oncology Institute, Inc., filed a Form 4 indicating no reportable transactions.

The Oncology Institute Director Anne McGeorge acquired 108,024 shares of common stock through restricted stock unit grants.

The Oncology Institute Director Mohit Kaushal acquired 91,049 shares of common stock through restricted stock unit grants on November 20, 2025.

Oncology Institute Director Gabriel Ling reported the acquisition of 83,333 shares of common stock through restricted stock unit grants.

The Oncology Institute, Inc. Director Karen Marie Johnson acquired 84,877 shares of common stock through restricted stock unit grants.

The Oncology Institute Director Mark L. Pacala acquired 81,790 shares of common stock through restricted stock unit grants.

The Oncology Institute Director Brad Hively increased his beneficial ownership by 74,074 shares through restricted stock unit grants.

The Oncology Institute Director Mark L. Pacala sold 50,000 shares of common stock for $4 per share, acquired from vested RSU awards, under a pre-arranged plan.

Oncology Institute Director Gabriel Ling reported changes in beneficial ownership of common stock through an in-kind distribution.

M33 Growth I L.P. and related entities reported in-kind distributions of Oncology Institute common stock, altering their beneficial ownership.

The Oncology Institute CEO Daniel Virnich acquired 6,464 shares of common stock through vested RSU awards.

The Oncology Institute's Chief Medical Officer, Yale Podnos, acquired 2,086 shares of common stock through a fully vested RSU award, increasing his direct beneficial ownership.

The Oncology Institute's CFO, Robert Ross Carter, acquired 195 shares of common stock through vested RSU awards.

The Oncology Institute CEO Daniel Virnich acquired 6,211 shares of common stock through vested RSU awards.

The Oncology Institute's Chief Medical Officer, Yale Podnos, acquired 1,508 shares of common stock through vested RSU awards.

M33 Growth I L.P. and related entities, identified as 10% owners and directors, sold 6.7 million shares of Oncology Institute, Inc. common stock for $3.09 per share.

The Oncology Institute Director Brad Hively sold 20,221 shares of common stock for $4.06 per share.

Richard A. Barasch, a director and 10% owner of Oncology Institute, Inc., has filed a Form 4 indicating he is no longer subject to Section 16 reporting obligations.

Oncology Institute Director and 10% owner Richard A. Barasch reported a distribution of 287,756 common shares from an entity he controls to another entity in which he holds a beneficial interest.

Kristin England, Chief Administrative Officer of Oncology Institute, Inc., acquired 98,037 shares of common stock through a fully vested Restricted Stock Unit (RSU) award.

A director of The Oncology Institute, Inc. exercised warrants, resulting in a net increase in their indirect beneficial ownership of common stock.

Richard A. Barasch, a Director and 10% Owner of The Oncology Institute, Inc., converted a significant portion of his Class A Common Equivalent Preferred Stock into common shares across two transactions in mid-June 2025.

M33 Growth I L.P., M33 Growth I GP LLC, and TOI M, LLC, entities associated with a director and 10% owner of The Oncology Institute, Inc., reported the sale of 750,000 shares of common stock for approximately $2.29 million.